An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is)
Song Wen,Thiquynhnga Nguyen,Min Gong,Xinlu Yuan,Chaoxun Wang,Jianlan Jin,Ligang Zhou
DOI: https://doi.org/10.2147/DMSO.S312527
2021-06-30
Abstract:Song Wen, 1, &ast Thiquynhnga Nguyen, 1, &ast Min Gong, 1 Xinlu Yuan, 1 Chaoxun Wang, 1 Jianlan Jin, 1 Ligang Zhou 1, 2 1 Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People's Republic of China; 2 Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ligang Zhou Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, People's Republic of China Tel +8613611927616 Email GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel antidiabetic medications associated with considerable cardiovascular benefits therapying treatment of diabetic patients. GLP-1 exhibits atherosclerosis resistance, whereas SGLT-2i acts to ameliorate the neuroendocrine state in the patients with chronic heart failure. Despite their distinct modes of action, both factors share pathways by regulating the central nervous system (CNS). While numerous preclinical and clinical studies have demonstrated that GLP-1 can access various nuclei associated with energy homeostasis and hedonic eating in the CNS via blood–brain barrier (BBB), research on the activity of SGLT-2is remains limited. In our previous studies, we demonstrated that both GLP-1 receptor agonists (GLP-1RAs) liraglutide and exenatide, as well as an SGLT-2i, dapagliflozin, could activate various nuclei and pathways in the CNS of Sprague Dawley (SD) rats and C57BL/6 mice, respectively. Moreover, our results revealed similarities and differences in neural pathways, which possibly regulated different metabolic effects of GLP-1RA and SGLT-2i via sympathetic and parasympathetic systems in the CNS, such as feeding, blood glucose regulation and cardiovascular activities (arterial blood pressure and heart rate control). In the present article, we extensively discuss recent preclinical studies on the effects of GLP-1RAs and SGLT-2is on the CNS actions, with the aim of providing a theoretical explanation on their mechanism of action in improvement of the macro-cardiovascular risk and reducing incidence of diabetic complications. Overall, these findings are expected to guide future drug design approaches. Keywords: autonomic nervous system, diabetic complications, brain nuclei, cardiovascular diseases, diabetes, obesity Type 2 diabetes (T2D) is currently a severe global public health issue, owing to the huge burden associated with management of microvascular and macrovascular complications. 1 These complications may not only impair a patient's physical or social functions, thereby reducing the quality of life, but also cause death. The pathogenesis of diabetes comprises various functional changes in multi-organs in response to systemic energy disarrangement, which were previously described as "ominous octet" by Professor Defronzo. 2 In recent years, there have been demands for re-classification of diabetes into various categories, namely severe autoimmune diabetes (SAID), severe insulin deficient diabetes (SIDD), severe insulin resistance diabetes (SIRD), mild obese related diabetes, and mild age-related diabetes (MARD), based on the ages of incidence, body mass index (BMI), hemoglobulin A1C (HbA1c), β-cell function, insulin resistance, and the positivity of glutamic acid decarboxylase autoantibody (GADA). 3 Generally, this re-classification was aimed at ensuring accurate stratification for diabetic complications and guiding personalized treatments. Previous studies have shown that the control level of glycemia is positive with reduced incidence of microvascular diseases, such as diabetic kidney diseases and diabetic retinopathy, although it has a weak relationship with improvement of macrovascular diseases. A previous meta-analysis 4 found that application of rosiglitazone, a thiazolidinedione (TZD) diabetic drug, could significantly increase the risk of myocardial infarction and death from cardiovascular causes, a concept that has subsequently been proven to be incorrect. However, these events forever changed the notion of the developing antidiabetic medications to endure tests with cardiovascular safety. Interestingly, multiple clinical trials have proved that the new medications, like glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter 2 inhibitors (SGLT-2is), not only guarantees cardiovascular safety by lowering glucose levels but also have the ability to improve clinical outcomes in -Abstract Truncated-